Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Queensland Health
Johnson and Johnson
Fish and Richardson
Boehringer Ingelheim

Generated: December 16, 2017

DrugPatentWatch Database Preview

ORAQIX Drug Profile

« Back to Dashboard

Which patents cover Oraqix, and what generic alternatives are available?

Oraqix is a drug marketed by Dentsply Pharm and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-three patent family members in twenty-nine countries.

The generic ingredient in ORAQIX is lidocaine; prilocaine. There are twenty-nine drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the lidocaine; prilocaine profile page.
Drug patent expirations by year for ORAQIX

Pharmacology for ORAQIX

Drug ClassAmide Local Anesthetic
Physiological EffectLocal Anesthesia

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dentsply PharmORAQIXlidocaine; prilocaineGEL;PERIODONTAL021451-001Dec 19, 2003RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ORAQIX

Country Document Number Estimated Expiration
Iceland4618► Subscribe
JapanH11501678► Subscribe
Israel122447► Subscribe
World Intellectual Property Organization (WIPO)9738675► Subscribe
Japan2004149544► Subscribe
Indonesia16420► Subscribe
China1188407► Subscribe
Hong Kong1010144► Subscribe
Australia716540► Subscribe
Argentina006484► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: